GGrantIndex
← Leaderboards

Andrew D Siderowf

University Of Pennsylvania

$3,949,530
Attributed
$4,944,785
Total exposure
5
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $439.7K · FY200522
$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22

Funding mix

By agency

NIH$4,944,785 · 4
AHRQ$0 · 1

By mechanism

P50$2,713,055 · 2
U24$1,492,883 · 1
U10$738,847 · 1
K08$0 · 1

Top collaborators

Most similar at University Of Pennsylvania

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Trials

Research focus

Clinical TrialsResourcesUniversitiesAgreementPennsylvaniaMonitorStagingParkinson DiseaseCohort StudiesHuman SubjectClinical ResearchEnsureMulti-Institutional Clinical TrialEnrollmentSiteResearch PersonnelPhiladelphiaProtocols DocumentationClinical InvestigatorProceduresCollaborationsCaringDesignFunding

Grant awards (30)

University of Pennsylvania Center for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT)$294,902
U24 · FY2022 · NS
University of Pennsylvania Center for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT)$294,902
U24 · FY2021 · NS
University of Pennsylvania Center for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT)$294,902
U24 · FY2020 · NS
University of Pennsylvania Center for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT)$294,902
U24 · FY2019 · NS
University of Pennsylvania Center for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT)$313,275
U24 · FY2018 · NS
A Multimodal Biomarker Approach to Evaluating and Predicting Cognitive Decline$277,203
P50 · FY2016 · NS · contact PI
A Multimodal Biomarker Approach to Evaluating and Predicting Cognitive Decline$277,203
P50 · FY2015 · NS · contact PI
A Multimodal Biomarker Approach to Evaluating and Predicting Cognitive Decline$274,737
P50 · FY2014 · NS · contact PI
A Multimodal Biomarker Approach to Evaluating and Predicting Cognitive Decline$267,502
P50 · FY2013 · NS · contact PI
A Multimodal Biomarker Approach to Evaluating and Predicting Cognitive Decline$277,203
P50 · FY2012 · NS · contact PI
Functional Consequence of Cognitive Impairment in PD$255,961
P50 · FY2011 · NS · contact PI
A Collaborative Center for the PD Neuroprotection Trial$96,974
U10 · FY2011 · NS · contact PI
Functional Consequence of Cognitive Impairment in PD$288,426
P50 · FY2010 · NS · contact PI
A Collaborative Center for the PD Neuroprotection Trial$108,668
U10 · FY2010 · NS · contact PI
A Collaborative Center for the PD Neuroprotection Trial$42,600
U10 · FY2010 · NS · contact PI
Functional Consequence of Cognitive Impairment in PD$263,656
P50 · FY2009 · NS · contact PI
A Collaborative Center for the PD Neuroprotection Trial$70,237
U10 · FY2009 · NS · contact PI
Functional Consequence of Cognitive Impairment in PD$261,881
P50 · FY2008 · NS · contact PI
A Collaborative Center for the PD Neuroprotection Trial$122,981
U10 · FY2008 · NS · contact PI
Functional Consequence of Cognitive Impairment in PD$269,283
P50 · FY2007 · NS · contact PI
A Collaborative Center for the PD Neuroprotection Trial$45,876
U10 · FY2007 · NS · contact PI
A Collaborative Center for the PD Neuroprotection Trial$11,700
U10 · FY2006 · NS · contact PI
A Collaborative Center for the PD Neuroprotection Trial$6,815
U10 · FY2005 · NS
HEALTH PREFERENCE ASSESSMENT IN PARKINSON'S DISEASE$0
K08 · FY2004 · HS
A Collaborative Center for the PD Neuroprotection Trial$116,498
U10 · FY2003 · NS
HEALTH PREFERENCE ASSESSMENT IN PARKINSON'S DISEASE$0
K08 · FY2003 · HS
A Collaborative Center for the PD Neuroprotection Trial$116,498
U10 · FY2002 · NS
HEALTH PREFERENCE ASSESSMENT IN PARKINSON'S DISEASE$0
K08 · FY2002 · HS
HEALTH PREFERENCE ASSESSMENT IN PARKINSON'S DISEASE$0
K08 · FY2001 · HS
HEALTH PREFERENCE ASSESSMENT IN PARKINSON'S DISEASE$0
K08 · FY2000 · HS